samedan logo
 
 
 
spacer
home > ebr > winter 2001 > biomics - 19th-21st november 2001, frankfurt
PUBLICATIONS
European Biopharmaceutical Review

Biomics - 19th-21st November 2001, Frankfurt

The IBC Life Sciences Conference, Biomics - Gene to protein to structure to drug, was held in Frankfurt 19th-21st November. This conference demonstrated how integrating genomics, proteomics, pharmacogenomics, structural biology and bioinformatics can provide well-validated drug targets for drug discovery. A key theme of the meeting was the degree to which laboratory academic research has been successfully industrialised. Many thousand gene or protein sequences can now be produced in a single day that were once the product of several years' postdoctoral research.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keith Chidwick, Consultant at Technomark Consulting Services Limited Keith Chidwick holds a PhD in Biochemistry from the University of London and an MBA from the Open University. His postdoctoral experience included a research fellowship at London Hospital Medical College before he became a Senior Lecturer in Biotechnology at the University of Westminster. His work included the evaluation of therapeutic recombinant proteins for inflammatory conditions. Prior to joining Technomark Keith was a Project Scientist at the Bio-Products Laboratory where he managed the research and scale-up of new pharmaceutical industrial processes. He has also managed projects with academic collaborators to improve an existing range of therapeutic proteins.
spacer
Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

OWEN MUMFORD LAUNCHES NEW 2-STEP SINGLE-USE AUTO-INJECTOR PLATFORM AIDAPTUS®

OXFORD, England, 22nd September - Owen Mumford Pharmaceutical Services, a division of Owen Mumford Ltd. has launched its new Aidaptus® auto-injector platform following successful completion of development.
More info >>

White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement